ORCA-3

The ORCA-3 trial mirrors the Phase 3 ORCA-2 trial and is designed to obtain additional safety and efficacy data.

Placebo-controlled & double-blind
3 treatment arms: Placebo vs 6 or 12 weeks cytisinicline
Cytisinicline treatment for 6 or 12 weeks
- Does longer treatment lead to better efficacy?
- Does continued treatment prevent early relapses?
Primary Endpoint: 4-week continuous abstinence ON treatment
Follow up to 6 months

ORCA-3 is being conducted at the following locations in the US.

Altoona Center for Clinical Research
https://www.altoonaarthritis.com/
800-924-7790 ext. 188

MediSphere Medical Research Center, LLC
https://www.medisphereresearch.com/
812-471-4110

Insight Research Institute
https://insightresearchinstitute.com/
810-213-8088

Jacksonville Center for Clinical Research
https://encoredocs.com/portfolio/smoking-cessation/
904-730-0101

Little Rock Allergy & Asthma Clinic
https://www.littlerockallergy.com/
1-800-514-4343

Clinical Research Associates, Inc.
https://clinicalresearchassociates.com/stop-smoking/
615-329-0197 Ext. 231

Health Research of Hampton Roads, Inc.
https://hrhr-inc.com/smoking-cessation/
757-591-8100

Alliance for Multispecialty Research
(AMR Phoenix)
https://crctrials.com/smoking-cessation/
602-759-7559

Trial Management Associates, Inc.
https://www.trialmgt.com/contact-us/
910-833-1954